Efficacy analysis will be according to the intent to treat (ITT) principle by last observation carried forward (LOCF).
Intent to Treat: Subjects will be included in the ITT analysis if they were randomized to study procedure group, had successfully completed the Baseline Standardization Phase and had received at least one study procedure administration (1 out of 8 procedures).
Last observation carried forward: Missing data will be handled by carrying forward the last observation.
STATISTICAL ANALYSIS
The primary analysis of efficacy will be through parametric analysis of variance (ANOVA) model.
The parametric ANOVA model will be applied with the mean change from baseline to endpoint in 3-recording average daily pain rating for the study hip as the dependent variable and procedure group as the independent variable of interest. A two-tailed significance level of 5% will be considered to be statistically significant.
Analysis by paired-samples t-test will also be conducted.
Secondary Measures Analysis
The secondary measures are continuous variables and will be analyzed through parametric analysis using ANOVA. A two-way significance level of 5% will be considered to be statistically significant.
The Resonator™ device is an Investigational Device limited by Federal (or United States)
law to investigational use. The Resonator™ device is not for sale, nor is the
Magneceutical®
Therapy generally available outside of Investigational Review Board (IRB) approved clinical studies.